Loading...
MVC logo

Metrovacesa S.A.BME:MVC Rapport sur les actions

Capitalisation boursière €1.6b
Prix de l'action
€10.70
€10.81
1.0% sous-évalué décote intrinsèque
1Y-2.3%
7D-11.3%
1D
Valeur du portefeuille
Voir

Metrovacesa S.A.

BME:MVC Rapport sur les actions

Capitalisation boursière : €1.6b

MVC Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Metrovacesa S.A. Concurrents

Historique des prix et performances

Résumé des hausses, des baisses et des variations du cours de l'action pour la période du 1er janvier au 31 décembre 2009 Metrovacesa
Historique des cours de bourse
Prix actuel de l'action€10.70
Plus haut sur 52 semaines€13.50
Plus bas sur 52 semaines€8.82
Bêta0.71
Variation sur 1 mois-9.01%
Variation sur 3 mois-2.28%
Variation sur 1 an-2.28%
Variation sur 3 ans53.74%
Variation sur 5 ans44.79%
Évolution depuis l'introduction en bourse-33.13%

Nouvelles et mises à jour récentes

Mise à jour du récit May 02

MVC: Slightly Higher Required Return And Rich P/E Will Constrain Future Upside

Analysts have kept their average price target for Metrovacesa broadly steady around €10.81, citing only slight shifts in discount rate, profit margin assumptions and future P/E expectations rather than any major change in the investment case. Valuation Changes Fair Value: The €10.81 fair value estimate is unchanged, indicating a stable central valuation point in the model.
Mise à jour du récit Apr 17

MVC: Higher Required Return And Rich P/E Will Pressure Future Returns

Analysts have kept their price target for Metrovacesa broadly unchanged at around €10.81 per share. The latest revisions reflect only very small model tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, rather than any shift in their core view.
Mise à jour du récit Apr 03

MVC: Stable Assumptions And Discount Rate Tweaks Will Guide Future Returns

Analysts keep their Metrovacesa price target steady at €10.81, indicating largely unchanged assumptions on fair value, growth, margins, and future P/E, with only minor adjustments to discount rates and long-term expectations. Valuation Changes Fair Value: €10.81 per share is unchanged, suggesting the core view of what the stock is worth on a fundamental basis remains the same.

Recent updates

Mise à jour du récit May 02

MVC: Slightly Higher Required Return And Rich P/E Will Constrain Future Upside

Analysts have kept their average price target for Metrovacesa broadly steady around €10.81, citing only slight shifts in discount rate, profit margin assumptions and future P/E expectations rather than any major change in the investment case. Valuation Changes Fair Value: The €10.81 fair value estimate is unchanged, indicating a stable central valuation point in the model.
Mise à jour du récit Apr 17

MVC: Higher Required Return And Rich P/E Will Pressure Future Returns

Analysts have kept their price target for Metrovacesa broadly unchanged at around €10.81 per share. The latest revisions reflect only very small model tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, rather than any shift in their core view.
Mise à jour du récit Apr 03

MVC: Stable Assumptions And Discount Rate Tweaks Will Guide Future Returns

Analysts keep their Metrovacesa price target steady at €10.81, indicating largely unchanged assumptions on fair value, growth, margins, and future P/E, with only minor adjustments to discount rates and long-term expectations. Valuation Changes Fair Value: €10.81 per share is unchanged, suggesting the core view of what the stock is worth on a fundamental basis remains the same.
Mise à jour du récit Mar 20

MVC: Dividend Outlook And Revised Assumptions Will Shape Future Return Balance

Analysts now set their fair value estimate for Metrovacesa at €10.81 per share, up from €10.63. This reflects updated assumptions around the discount rate, revenue growth, profit margin and future P/E.
Mise à jour du récit Mar 06

MVC: Lower Growth Assumptions And Elevated P/E Will Sustain Bearish View

Analysts have modestly lowered their price target on Metrovacesa to €9.30, citing updated assumptions for revenue growth, profit margins and the future P/E multiple, while keeping their fair value estimate unchanged at €9.30. Valuation Changes Fair Value: The fair value estimate is unchanged at €9.30 per share, indicating no revision to the overall valuation outcome.
Mise à jour du récit Feb 20

MVC: Dividend Outlook And Updated Assumptions Will Shape Future Return Balance

Analysts have slightly trimmed their fair value estimate for Metrovacesa from €10.83 to €10.63, citing updated assumptions around discount rates, expected revenue growth, margins and future P/E levels. Valuation Changes Fair Value: Trimmed slightly from €10.83 to €10.63 per share.
Mise à jour du récit Feb 06

MVC: Lower Discount Rate And High P/E Will Sustain Bearish View

Analysts have slightly raised their price target on Metrovacesa, citing updated assumptions for the discount rate, revenue growth, profit margins and future P/E, which together indicate a modestly higher fair value per share in euro terms. Valuation Changes Fair Value: unchanged at €9.30 per share.
Mise à jour du récit Jan 23

MVC: Dividend Reserve Plans And P/E Revisions Will Guide Cautious Outlook

Analysts have maintained their Metrovacesa fair value target at €9.30, citing a combination of updated assumptions that include slightly lower discount rates, higher revenue growth expectations, softer profit margins and a higher future P/E multiple in their latest models. What's in the News Metrovacesa has scheduled a Special and Extraordinary Shareholders Meeting for November 25, 2025, at 13:00 Central European Standard Time in Madrid, Spain (Key Developments).
Mise à jour du récit Jan 08

MVC: Dividend Proposal At Extraordinary Meeting Will Support Bullish Thesis

Analysts have revised their price target on Metrovacesa from €11.80 to €13.10, citing updated assumptions around discount rates, revenue growth, profit margins, and the future P/E multiple. What's in the News Metrovacesa has scheduled a Special and Extraordinary Shareholders Meeting for November 25, 2025, at 13:00 Central European Standard Time in Madrid, Spain (calle principe de vergara 187, plaza de rodrigo uria, madrid) (Key Developments) The meeting agenda includes a proposal to discuss the distribution of dividends from freely distributable reserves, which may be relevant if you are focusing on potential cash returns to shareholders (Key Developments) The notice also refers to discussion of other matters at the meeting, indicating that additional shareholder topics could be addressed beyond dividends (Key Developments) Valuation Changes Fair Value Estimate was revised from €11.80 to €13.10, indicating a higher assessed value per share.
Mise à jour du récit Dec 24

MVC: Dividend Reserve Plans Will Shape A Cautious Medium-Term Outlook

Analysts have raised their price target on Metrovacesa from €6.50 to €9.30, citing higher expected revenue growth, improved profit margins, and a modestly richer future P/E multiple, despite a slightly higher discount rate. What's in the News Metrovacesa has called a special shareholders meeting for November 25, 2025, at 13:00 CET in Madrid to address key corporate matters.
Article d’analyse Dec 20

Metrovacesa S.A. (BME:MVC) Shares Could Be 23% Below Their Intrinsic Value Estimate

Key Insights Metrovacesa's estimated fair value is €11.52 based on 2 Stage Free Cash Flow to Equity Current share price...
Mise à jour du récit Dec 10

MVC: Dividend Decision And Revised Outlook Will Shape Balanced Return Prospects

Analysts have raised their price target on Metrovacesa from €9.81 to €10.83, citing a higher long term fair value despite moderating assumptions for revenue growth, profit margins and future earnings multiples. What's in the News Metrovacesa has scheduled a special and extraordinary shareholders meeting for November 25, 2025, at 13:00 Central European Standard Time in Madrid, Spain (Key Developments) The main agenda item for the upcoming meeting is the potential distribution of dividends from freely distributable reserves, which could affect shareholder returns policy (Key Developments) Shareholders will also address other unspecified matters at the meeting, leaving scope for additional corporate or capital structure decisions (Key Developments) Valuation Changes Fair Value: raised slightly from €9.81 to €10.83 per share, reflecting a modest uplift in long term valuation.
Article d’analyse Oct 02

Should You Think About Buying Metrovacesa S.A. (BME:MVC) Now?

Metrovacesa S.A. ( BME:MVC ), is not the largest company out there, but it had a relatively subdued couple of weeks in...
Article d’analyse Jul 25

Calculating The Fair Value Of Metrovacesa S.A. (BME:MVC)

Key Insights Using the 2 Stage Free Cash Flow to Equity, Metrovacesa fair value estimate is €12.58 Metrovacesa's €10.15...
Article d’analyse May 04

Does Metrovacesa (BME:MVC) Have A Healthy Balance Sheet?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Article d’analyse Apr 12

Are Investors Undervaluing Metrovacesa S.A. (BME:MVC) By 40%?

Key Insights The projected fair value for Metrovacesa is €16.96 based on 2 Stage Free Cash Flow to Equity Metrovacesa...
Article d’analyse Feb 26

Metrovacesa's (BME:MVC) Performance Is Even Better Than Its Earnings Suggest

Even though Metrovacesa S.A.'s ( BME:MVC ) recent earnings release was robust, the market didn't seem to notice. We...
User avatar
Nouveau récit Feb 19

Will Leverage Undersupplied Spanish Housing Market For Future Opportunities

High presales coverage allows focus on margin maximization, boosting future net margins amid an undersupplied market.
Article d’analyse Feb 07

Is It Time To Consider Buying Metrovacesa S.A. (BME:MVC)?

While Metrovacesa S.A. ( BME:MVC ) might not have the largest market cap around , it maintained its current share price...
Article d’analyse Dec 13

An Intrinsic Calculation For Metrovacesa S.A. (BME:MVC) Suggests It's 44% Undervalued

Key Insights Metrovacesa's estimated fair value is €16.39 based on 2 Stage Free Cash Flow to Equity Metrovacesa's €9.13...
Article d’analyse Sep 12

Estimating The Fair Value Of Metrovacesa S.A. (BME:MVC)

Key Insights The projected fair value for Metrovacesa is €9.93 based on 2 Stage Free Cash Flow to Equity Metrovacesa's...
Article d’analyse Aug 01

We Think Metrovacesa's (BME:MVC) Profit Is Only A Baseline For What They Can Achieve

The subdued stock price reaction suggests that Metrovacesa S.A.'s ( BME:MVC ) strong earnings didn't offer any...
Article d’analyse Jul 17

Is Now An Opportune Moment To Examine Metrovacesa S.A. (BME:MVC)?

While Metrovacesa S.A. ( BME:MVC ) might not have the largest market cap around , it saw significant share price...
Article d’analyse May 28

A Look At The Intrinsic Value Of Metrovacesa S.A. (BME:MVC)

Key Insights Using the 2 Stage Free Cash Flow to Equity, Metrovacesa fair value estimate is €9.31 Current share price...
Article d’analyse May 01

We Think Metrovacesa (BME:MVC) Can Stay On Top Of Its Debt

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Article d’analyse Mar 27

Is Now An Opportune Moment To Examine Metrovacesa S.A. (BME:MVC)?

While Metrovacesa S.A. ( BME:MVC ) might not have the largest market cap around , it received a lot of attention from a...
Article d’analyse Feb 12

A Look At The Fair Value Of Metrovacesa S.A. (BME:MVC)

Key Insights The projected fair value for Metrovacesa is €9.08 based on 2 Stage Free Cash Flow to Equity Current share...
Article d’analyse Nov 05

Does Metrovacesa (BME:MVC) Have A Healthy Balance Sheet?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Article d’analyse Jul 05

These 4 Measures Indicate That Metrovacesa (BME:MVC) Is Using Debt Extensively

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Article d’analyse May 21

Is Now An Opportune Moment To Examine Metrovacesa S.A. (BME:MVC)?

While Metrovacesa S.A. ( BME:MVC ) might not be the most widely known stock at the moment, it saw significant share...
Article d’analyse Apr 19

Estimating The Intrinsic Value Of Metrovacesa S.A. (BME:MVC)

Key Insights Using the 2 Stage Free Cash Flow to Equity, Metrovacesa fair value estimate is €7.36 Current share price...
Article d’analyse Dec 02

Does Metrovacesa (BME:MVC) Have A Healthy Balance Sheet?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Article d’analyse Sep 23

Is It Too Late To Consider Buying Metrovacesa S.A. (BME:MVC)?

While Metrovacesa S.A. ( BME:MVC ) might not be the most widely known stock at the moment, it received a lot of...
Article d’analyse May 19

Estimating The Intrinsic Value Of Metrovacesa S.A. (BME:MVC)

Does the May share price for Metrovacesa S.A. ( BME:MVC ) reflect what it's really worth? Today, we will estimate the...
Article d’analyse Mar 05

Metrovacesa's (BME:MVC) Strong Earnings Are Of Good Quality

Metrovacesa S.A. ( BME:MVC ) just reported healthy earnings but the stock price didn't move much. We think that...
Article d’analyse Feb 16

Would Metrovacesa (BME:MVC) Be Better Off With Less Debt?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Article d’analyse Oct 05

Does Metrovacesa (BME:MVC) Have A Healthy Balance Sheet?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Article d’analyse Jul 02

Is Metrovacesa S.A. (BME:MVC) Worth €6.7 Based On Its Intrinsic Value?

Today we will run through one way of estimating the intrinsic value of Metrovacesa S.A. ( BME:MVC ) by projecting its...
Article d’analyse May 06

Is Metrovacesa (BME:MVC) Using Too Much Debt?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Article d’analyse Apr 06

Is Metrovacesa S.A. (BME:MVC) A Strong Dividend Stock?

Is Metrovacesa S.A. ( BME:MVC ) a good dividend stock? How can we tell? Dividend paying companies with growing earnings...
Article d’analyse Mar 15

Metrovacesa (BME:MVC) Share Prices Have Dropped 51% In The Last Three Years

Metrovacesa S.A. ( BME:MVC ) shareholders should be happy to see the share price up 12% in the last month. But that...
Article d’analyse Feb 16

Loss-Making Metrovacesa S.A. (BME:MVC) Set To Breakeven

We feel now is a pretty good time to analyse Metrovacesa S.A.'s ( BME:MVC ) business as it appears the company may be...
Article d’analyse Jan 26

When Should You Buy Metrovacesa S.A. (BME:MVC)?

Metrovacesa S.A. ( BME:MVC ), might not be a large cap stock, but it led the BME gainers with a relatively large price...
Article d’analyse Jan 05

A Look At The Fair Value Of Metrovacesa S.A. (BME:MVC)

In this article we are going to estimate the intrinsic value of Metrovacesa S.A. ( BME:MVC ) by taking the expected...
Article d’analyse Dec 14

If You Had Bought Metrovacesa's (BME:MVC) Shares A Year Ago You Would Be Down 24%

Metrovacesa S.A. ( BME:MVC ) shareholders should be happy to see the share price up 11% in the last month. But that...

Rendement pour les actionnaires

MVCES Real EstateES Marché
7D-11.3%-3.3%2.1%
1Y-2.3%-1.3%22.7%

Rendement vs Industrie: MVC correspondait au secteur Spanish Real Estate qui a rapporté -1.3 % au cours de l'année écoulée.

Rendement vs marché: MVC a sous-performé le marché Spanish qui a rapporté 22.7 % au cours de l'année écoulée.

Volatilité des prix

Is MVC's price volatile compared to industry and market?
MVC volatility
MVC Average Weekly Movement5.6%
Real Estate Industry Average Movement3.8%
Market Average Movement3.9%
10% most volatile stocks in ES Market6.8%
10% least volatile stocks in ES Market0.9%

Cours de l'action stable: Le cours de l'action de MVC a été volatil au cours des 3 derniers mois par rapport au marché Spanish.

Volatilité au fil du temps: La volatilité hebdomadaire de MVC ( 6% ) est restée stable au cours de l'année écoulée, mais reste supérieure à 75 % des actions de Spanish.

À propos de l'entreprise

FondéeSalariésPDGSite web
1918214Jorge de Leza Eguigurenwww.metrovacesa.com

Metrovacesa S.A. est une société de promotion immobilière en Espagne. La société développe et vend des locaux résidentiels et commerciaux, ainsi que des terrains. Metrovacesa S.A. a été fondée en 1918 et est basée à Madrid, en Espagne.

Metrovacesa S.A. Résumé des fondamentaux

Comment les bénéfices et les revenus de Metrovacesa se comparent-ils à sa capitalisation boursière ?
MVC statistiques fondamentales
Capitalisation boursière€1.62b
Bénéfices(TTM)€56.86m
Recettes(TTM)€708.37m
28.5x
Ratio P/E
2.3x
Ratio P/S

Le site MVC est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
MVC compte de résultat (TTM)
Recettes€708.37m
Coût des recettes€528.83m
Marge brute€179.54m
Autres dépenses€122.68m
Les revenus€56.86m

Derniers bénéfices déclarés

Dec 31, 2025

Prochaine date de publication des résultats

Jul 22, 2026

Résultat par action (EPS)0.38
Marge brute25.35%
Marge bénéficiaire nette8.03%
Ratio dettes/capitaux propres30.7%

Quelles ont été les performances à long terme de MVC?

Voir les performances historiques et les comparaisons

Dividendes

14.8%
Rendement actuel des dividendes
n/a
Ratio de distribution

Le site MVC verse-t-il des dividendes fiables ?

Voir MVC l'historique des dividendes et les indices de référence
Quand faut-il acheter MVC pour recevoir un dividende à venir ?
Metrovacesa dates des dividendes
Date ex-dividendeMay 20 2026
Date de paiement du dividendeMay 22 2026
Jours jusqu'au dividende Ex2 days
Jours jusqu'à la date de paiement du dividende0 days

Le site MVC verse-t-il des dividendes fiables ?

Voir MVC l'historique des dividendes et les indices de référence

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/05/21 03:34
Cours de l'action en fin de journée2026/05/21 00:00
Les revenus2025/12/31
Revenus annuels2025/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Metrovacesa S.A. est couverte par 22 analystes. 2 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Ignacio RomeroBanco de Sabadell. S.A.
null nullBanco de Sabadell. S.A.
Mariano Miguel HidalgoBanco Santander